Search

Intellia Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

14.26 -6.55

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.26

Max

14.63

Galvenie mērījumi

By Trading Economics

Ienākumi

106M

-96M

Pārdošana

-8M

15M

EPS

-0.81

Peļņas marža

-639.494

Darbinieki

377

EBITDA

1.4M

-94M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+50.35% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 6. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

843M

2.5B

Iepriekšējā atvēršanas cena

20.81

Iepriekšējā slēgšanas cena

14.26

Ziņu noskaņojums

By Acuity

61%

39%

276 / 342 Rangs Healthcare

Intellia Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. jūl. 23:06 UTC

News

PepsiCo shares are lower in after-market hours following a downgrade to Hold by Citi, with the price target reduced to $145 from $170.

2026. g. 10. jūl. 23:01 UTC

News

Cognizant Technology Solutions received court approval for a $5.5 million settlement in a stockholder lawsuit, with shares trading higher in after-market hours.

2026. g. 10. jūl. 20:13 UTC

ETF Constituents
News
Correlated Moves

Vanguard Large-Cap ETF is trading lower in after-market hours, influenced by slight losses in top holdings META, AAPL, ABBV, MA, and NVDA.

2026. g. 10. jūl. 20:07 UTC

News
Correlated Moves

Ethereum is gaining as Circle Internet Group receives approval for a national trust bank, boosting interest in digital assets amid geopolitical tensions.

2026. g. 10. jūl. 20:07 UTC

News

Costco Wholesale shares are higher today, recovering from earlier losses despite concerns over moderating growth and sustainability amid easing fuel prices.

2026. g. 10. jūl. 20:07 UTC

News
Social Media

Micron Technology shares are lower amid a semiconductor sector selloff, despite announcing over $250 billion in U.S. investment for AI memory chips.

2026. g. 10. jūl. 20:07 UTC

News
Social Media
Event

Netflix Inc shares are lower amid concerns about declining subscriber engagement. The company is exploring strategies to enhance viewer interest, including live TV channels.

2026. g. 10. jūl. 20:07 UTC

Correlated Moves
News

Bitcoin is trading higher as Circle Internet Group gains approval for a national trust bank focused on digital asset custody services. Ethereum also shows notable increases.

2026. g. 10. jūl. 20:07 UTC

Correlated Moves
News

Bitcoin is trading higher since Thursday's close, supported by Circle Internet Group's approval for a national trust bank focused on digital asset custody services.

2026. g. 10. jūl. 20:07 UTC

Correlated Moves
News

Ethereum is gaining amid increased market interest following Circle Internet Group's trust bank approval. Geopolitical tensions are also driving investors toward cryptocurrencies.

2026. g. 10. jūl. 20:06 UTC

News

Autodesk Inc shares are lower today following a negative report from StockStory, which advises avoiding the stock due to slower revenue growth and high payback periods.

2026. g. 10. jūl. 20:06 UTC

News

United Airlines shares are lower amid concerns following Delta's strong earnings report, which raised expectations for upcoming results but highlighted pricing power challenges.

2026. g. 10. jūl. 20:06 UTC

Correlated Moves
Social Media
News

Applied Materials shares advance as Needham raises price target to $740 and Stifel lifts its target to $650, reflecting strong demand in the semiconductor sector.

2026. g. 10. jūl. 20:03 UTC

News
Social Media

NVIDIA shares are higher today as Morgan Stanley reaffirms its Overweight rating and U.S. eases AI chip export curbs to the UAE.

2026. g. 10. jūl. 20:02 UTC

News

Vertex Pharmaceuticals is lower today amid significant declines in the Biotechnology sub-sector, marking a shift from recent higher daily closes.

2026. g. 10. jūl. 20:02 UTC

News
Social Media

Fox Corp shares are higher, supported by record FIFA World Cup viewership and an upgrade to Buy from Rothschild Redburn, raising the price target to $71.

2026. g. 10. jūl. 20:01 UTC

News

Gilead Sciences is highlighted as a resilient dividend stock, yet shares are trading lower amid broader market volatility and recent declines.

2026. g. 10. jūl. 19:56 UTC

Social Media
News

Dollar Tree shares are higher after a positive UBS assessment, signaling an inflection point for the retailer amid cautious market sentiment ahead of key economic data.

2026. g. 10. jūl. 19:51 UTC

Social Media
News

Take-Two Interactive is under pressure amid sector weakness, with a recent report advising against the stock due to limited cash flow and declining sales projections.

2026. g. 10. jūl. 19:47 UTC

ETF Constituents
News
Correlated Moves

The Vanguard Small-Cap ETF is lower amid ongoing geopolitical tensions and declines among key holdings, including SRPT, AXON, NTRA, LAMR, and IONS.

2026. g. 10. jūl. 19:47 UTC

News
Social Media

Tesla Inc's stock is higher, supported by increased buying interest and strong Model Y sales in China, with shares reaching an intraday high of $407.85.

2026. g. 10. jūl. 19:47 UTC

News

PayPal Holdings Inc is gaining momentum, driven by strong performance in Venmo and Braintree, alongside a clearer operational framework under CEO Dan Schulman.

2026. g. 10. jūl. 19:47 UTC

News
Social Media

Intel Corp's stock is lower as AMD's data center revenue outpaces Intel's, raising investor concerns amid ongoing profitability challenges.

2026. g. 10. jūl. 19:47 UTC

News

Qualcomm shares are lower at about $188.81 amid mixed options sentiment and a decline in implied volatility ahead of the upcoming earnings report.

2026. g. 10. jūl. 19:47 UTC

Correlated Moves
Social Media
News

Broadcom shares are lower despite a $30 billion agreement with Apple to produce custom silicon components through 2031, amid broader semiconductor industry concerns.

2026. g. 10. jūl. 19:46 UTC

News
Social Media

Rothschild Redburn upgraded Fox Corp to Buy, raising the price target to $71. The stock remains higher since Thursday's close despite earlier session pullbacks.

2026. g. 10. jūl. 19:46 UTC

News

American Airlines Group faces challenges ahead of its earnings report, with shares declining amid cautious sentiment following Delta Air Lines' strong Q2 performance.

2026. g. 10. jūl. 19:41 UTC

Macro News
ETF Constituents
News

FXI is trading higher following Shein's Hong Kong IPO approval, boosting confidence in Chinese equities. Key holdings XIACY and TCOM also show notable returns.

2026. g. 10. jūl. 19:36 UTC

News

CSX shares rise on TD Cowen, JP Morgan upgrades ahead of Q2 report.

2026. g. 10. jūl. 19:36 UTC

News
Social Media

Microsoft shares advanced after Argus reaffirmed a Buy rating, lowering the price target to $510. The stock remains near the upper end of its one-month range.

Salīdzinājums

Cenas izmaiņa

Intellia Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

50.35% augšup

Prognoze 12 mēnešiem

Vidējais 21.38 USD  50.35%

Augstākais 49 USD

Zemākais 8 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Intellia Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

18 ratings

8

Pirkt

8

Turēt

2

Pārdot

Noskaņojums

By Acuity

276 / 342 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat